GLP-1 and Fertility: Emerging Evidence for Women With Obesity, Insulin Resistance, and PMOS

GLP-1 receptor agonists improve fertility in women with PMOS and insulin resistance. That is the direction the evidence is pointing. Multiple clinical trials now show that semaglutide, liraglutide, and exenatide restore ovulatory cycles, reduce androgen excess, and improve menstrual regularity in women whose fertility has been disrupted by metabolic dysfunction. If you have PMOS, insulin resistance, or obesity, and you have struggled to conceive or been told your cycles are irregular, GLP-1 therapy is worth understanding in depth.

This is not a replacement for fertility treatment. It is a metabolic intervention that targets the biological roots of ovulatory failure — roots that standard reproductive medicine does not always address.

What Is the Link Between GLP-1, PMOS, and Fertility?

The connection runs through insulin resistance. Most women with polycystic metabolic-ovarian syndrome (PMOS) have significant insulin resistance — estimates put it at 65–80% across all phenotypes, regardless of body weight.1 Chronically elevated insulin drives the ovary to overproduce androgens. Elevated androgens disrupt follicular development. Disrupted follicular development suppresses ovulation. The result: irregular or absent cycles, anovulatory infertility, and poor egg quality.

GLP-1 receptor agonists break this chain. They lower circulating insulin by improving insulin sensitivity. Lower insulin means less androgen stimulation of the ovaries. Less ovarian androgen means better follicular development. Better follicular development restores ovulation.

That is the core mechanism — but it is not the only one.

How Obesity Compounds Fertility Problems in PMOS

Excess adipose tissue is not inert. It is metabolically active. In women with obesity and PMOS, visceral fat amplifies the insulin-androgen cycle through several parallel routes:

• Excess adipokines — inflammatory cytokines from visceral fat (TNF-α, IL-6) worsen insulin resistance at the cellular level
• Aromatase overexpression — fat tissue converts androgens to oestrogen peripherally, disrupting the hormonal feedback that governs ovulation
• Leptin resistance — elevated leptin from excess fat impairs hypothalamic signalling that drives the reproductive hormone cascade
• Direct oocyte toxicity — the inflammatory environment damages egg quality even before ovulation occurs

Obesity also disrupts the hypothalamic-pituitary-ovarian (HPO) axis — the signalling chain through which the brain controls ovarian function. Elevated insulin and chronic inflammation impair hypothalamic sensitivity to kisspeptin, the neuropeptide that triggers the gonadotropin-releasing hormone (GnRH) pulse. Without a proper GnRH pulse, the pituitary fails to release adequate FSH and LH. Without FSH and LH, follicles cannot mature and ovulation cannot occur.2

This is why weight alone is such a powerful predictor of fertility outcomes in PMOS. And it is why therapies that address the metabolic root — not just the symptom — matter.

GLP-1 Receptors Exist in Reproductive Tissue

Here is something most patients are not told: GLP-1 receptors are not confined to the gut and pancreas. They are expressed in the hypothalamus, pituitary, ovaries, and uterus.3

This matters because it means GLP-1 receptor agonists can exert direct effects on the reproductive system — not just indirect effects mediated by weight loss. Preclinical research has identified several mechanisms:

• GLP-1 influences GnRH pulsatility in hypothalamic neurons via the kisspeptin system, directly modulating the HPO axis signal chain4
• GLP-1R activation in granulosa cells promotes cell proliferation and inhibits apoptosis, supporting healthy follicular development5
• GLP-1 agonists reduce ovarian androgen synthesis by modulating steroidogenic enzyme expression (StAR, P450scc, 3β-HSD) in ovarian tissue5
• GLP-1 has anti-inflammatory effects in the ovary and endometrium, improving the local environment for follicular maturation and implantation6

This dual mechanism — systemic metabolic correction plus direct reproductive tissue effects — makes GLP-1 receptor agonists uniquely relevant for fertility in metabolic PMOS.

What the Clinical Evidence Shows

GLP-1 Therapy and Ovulation Restoration in PMOS Insulin Resistance

The clinical data is building. Here is a summary of the key evidence to date.

Semaglutide (low-dose, 0.5 mg weekly): A 2023 study in women with PMOS who had failed lifestyle modification found that semaglutide produced clinically significant weight loss in nearly 80% of participants. This was associated with measurable improvement in fasting glucose, HOMA-IR, and menstrual cycle regularity.7

Liraglutide (26-week RCT): A randomised double-blind, placebo-controlled trial by Nylander et al. evaluated liraglutide specifically for ovarian dysfunction markers. The treatment group showed improved bleeding regularity, reduced ovarian volume, lower free testosterone, and higher SHBG — all markers associated with restored ovulatory function.7

Exenatide (meta-analysis data): Multiple clinical trials found that exenatide — both in monotherapy and combined with metformin — improved menstrual regularity and ovulation rate in overweight and obese women with PMOS. This directly translates to enhanced fertility outcomes.8

Two-year durability data: A 2024 observational study followed 25 women with PMOS and obesity who used semaglutide (up to 1 mg weekly) for 16 weeks as an add-on to metformin, then continued on metformin for two years. Despite some weight regain after semaglutide discontinuation, women retained a statistically significant net weight loss from baseline. Metabolic and hormonal improvements partially persisted — though the data also underline that ongoing treatment produces better sustained outcomes than short-term use.7

Meta-analysis (2023): A systematic review and meta-analysis examining GLP-1 RAs in PMOS found improvements in pregnancy rate, menstrual cyclicity, BMI, waist circumference, fasting insulin, HOMA-IR, LH/FSH ratio, total testosterone, and SHBG across included RCTs.9

European Journal of Endocrinology systematic review (2026): A comprehensive meta-analysis of 11 RCTs confirmed the metabolic and some endocrine benefits of GLP-1 RAs in PMOS, reinforcing that weight-mediated improvements in hormonal markers are reproducible across populations and treatment regimens.10

The consistency is notable. Across different GLP-1 agents, different dosing protocols, and different study populations, the direction of effect on ovulatory function and metabolic markers is the same.

GLP-1 vs. Metformin for PMOS Fertility: A Clinical Comparison

Metformin has been first-line pharmacological treatment for insulin resistance in PMOS for decades. GLP-1 receptor agonists are newer. How do they compare for fertility outcomes?

The clinical takeaway: GLP-1 RAs produce larger and more consistent weight loss than metformin, and greater weight loss correlates strongly with better hormonal and reproductive outcomes. For women with significant obesity or metformin-resistant insulin resistance, GLP-1 RAs represent a meaningful step up.8

The two are not mutually exclusive. Multiple studies have examined GLP-1 agonists as add-on therapy to metformin, with additive benefits.7

Who Is Most Likely to Benefit?

Not every woman with PMOS has the same fertility problem. GLP-1 therapy for fertility is most clearly supported by the evidence in these profiles:

1. Women with PMOS and significant obesity (BMI ≥ 30) The greatest fertility response to GLP-1 therapy is seen in women where metabolic dysfunction — not primary ovarian pathology — is the main driver of anovulation. Clinically meaningful weight loss (≥ 5% body weight) frequently triggers ovulation restoration in this group.

2. Women with documented insulin resistance (elevated fasting insulin, HOMA-IR > 2.5) Hyperinsulinaemia is the proximate cause of ovarian androgen excess in most women with metabolic PMOS. GLP-1 RAs target this directly. Women with measurably elevated HOMA-IR at baseline show the greatest hormonal response.

3. Women with PMOS who have failed first-line lifestyle intervention Studies specifically enrolled women who were unresponsive to lifestyle modification. GLP-1 RAs produced weight loss and cycle restoration in women who had not responded to diet and exercise alone.7

4. Women preparing for IVF with obesity or poor prior response Pilot studies suggest GLP-1-mediated weight loss before IVF cycles may improve ovarian response, oocyte quality, and outcomes in obese women with prior poor response — though this remains an emerging area requiring larger prospective trials.11

5. Women with PMOS and concomitant pre-diabetes or metabolic syndrome The metabolic burden of elevated A1c, dyslipidaemia, and visceral adiposity compounds ovarian dysfunction. GLP-1 RAs address this systemic picture comprehensively.

GLP-1 and Fertility: What the Evidence Does Not Yet Confirm

Clinical honesty matters here. There is genuine signal in the data, but there are also gaps.

Pregnancy outcomes data is limited. Most studies measure ovulation rate, menstrual regularity, and hormonal markers as surrogate endpoints — not live birth rates. Confirming that restored ovulation translates to confirmed pregnancies and healthy outcomes requires larger and longer trials.12

GLP-1 must be discontinued before conception. Semaglutide has a half-life of approximately 7 days. Current guidance recommends stopping GLP-1 RAs at least 2 months before planned conception due to limited human pregnancy data and theoretical developmental risks from animal studies.11 This is not a minor consideration — a patient who normalises her cycles on semaglutide needs a transition plan before she attempts to conceive.

Benefits partially reverse on discontinuation. The 2024 Jensterle data showed partial weight and hormonal regression after stopping semaglutide — though net gains from baseline persisted.7 For women approaching fertility treatment, the timing and transition strategy around GLP-1 use must be clinically managed.

Androgens: effect is inconsistent. Some studies show significant reductions in total testosterone on GLP-1 RAs. A 2026 Cureus meta-analysis found no significant overall effect on total testosterone (SMD: −0.10; 95% CI: −0.38 to 0.18), though SHBG consistently increased, effectively reducing free androgen levels.13 The mechanism matters: SHBG rise from improved insulin sensitivity may be the primary androgenic pathway, not direct androgen reduction.

The Metabolic Workup Before GLP-1 Therapy for PMOS Fertility

Starting GLP-1 therapy for fertility without a metabolic baseline is poor clinical practice. A proper workup establishes whether insulin resistance is the primary driver of ovulatory failure and identifies any contraindications.

Step 1: Confirm insulin resistance Fasting insulin, fasting glucose, and HOMA-IR should be measured. Many women with PMOS have normal fasting glucose but significantly elevated insulin — the earliest detectable sign of metabolic dysfunction. Learn more about the fasting insulin test at Meto.

Step 2: Assess the full metabolic-hormonal picture A comprehensive panel should include HbA1c, lipid panel, liver enzymes, testosterone (total and free), SHBG, LH, FSH, AMH, and pelvic ultrasound. This rules out other causes of anovulation and quantifies the metabolic burden. Meto's comprehensive lab panels are designed to capture this full picture in a single draw.

Step 3: Rule out contraindications to GLP-1 therapy A history of pancreatitis, personal or family history of medullary thyroid carcinoma, or MEN2 syndrome are contraindications to GLP-1 RAs.

Step 4: Set fertility timing expectations If conception is being planned within a 6-month window, the requirement to discontinue GLP-1 therapy 2 months before trying to conceive should factor into treatment planning. The goal is to use GLP-1 therapy to restore metabolic and ovulatory function, then transition to a conception-safe maintenance strategy.

Step 5: Establish monitoring cadence Ovulation tracking (cycle length, LH surge, progesterone on day 21), weight, fasting insulin, and HOMA-IR should be followed at 3-month intervals. This confirms whether the metabolic intervention is translating into reproductive benefit. Read more about managing insulin resistance at the root cause level.

The Bigger Picture: Metabolic Health as a Fertility Strategy

The emerging science around GLP-1 and fertility is not just about a medication. It reflects a deeper clinical truth: ovulatory dysfunction in women with PMOS is often a metabolic problem masquerading as a reproductive one.

When the metabolic disease is not treated, fertility treatment operates against the biological current. IVF cycles in obese women with insulin resistance have lower success rates. Ovulation induction with clomiphene or letrozole fails more often. The endometrium is less receptive. Miscarriage rates are higher.

Addressing insulin resistance, visceral fat, and chronic hyperinsulinaemia changes the baseline. It makes the reproductive system more amenable to treatment — whether that treatment is natural conception, ovulation induction, or assisted reproduction.

GLP-1 receptor agonists are currently the most effective pharmacological tool for producing the magnitude of weight loss and insulin sensitisation that drives this reversal. The clinical evidence is early but consistent. The biological rationale is sound. The conversation between metabolic medicine and reproductive medicine is overdue.

Conclusion

GLP-1 fertility outcomes in PMOS and insulin resistance are one of the most promising areas of emerging metabolic research. The evidence supports GLP-1 receptor agonists as an effective intervention for women whose anovulatory infertility is driven by insulin resistance, hyperandrogenism, and obesity. Ovulation restoration, improved menstrual regularity, and reduced androgen burden are documented across multiple RCTs and a growing meta-analytic literature.

The treatment is not a standalone fertility drug. It is a metabolic intervention that corrects the biological environment in which reproduction must occur. Managed properly — with a complete metabolic workup, appropriate fertility timing, and a planned pre-conception transition — it gives women with PMOS a viable clinical path that standard reproductive medicine has historically underserved.

If you have PMOS, insulin resistance, or obesity, and fertility is a goal, the conversation starts with your metabolic data.

Get a PMOS and Fertility Metabolic Plan Through a Meto Specialist

Meto specialises in the metabolic-hormonal conditions that drive fertility disruption in women with PMOS — including insulin resistance, hyperandrogenism, and obesity. Our clinicians combine comprehensive lab evaluation with physician-led treatment, including GLP-1 therapy where clinically appropriate, in a structured programme designed for your specific metabolic profile.

Start your metabolic assessment →

Frequently Asked Questions

Can GLP-1 medications help me get pregnant if I have PMOS?

GLP-1 receptor agonists are not fertility drugs, but they address the metabolic dysfunction that drives anovulatory infertility in many women with PMOS. Multiple RCTs have demonstrated improved ovulation rates and menstrual regularity in women with PMOS and insulin resistance after GLP-1 therapy. The primary mechanism is reducing hyperinsulinaemia and body weight, which lowers ovarian androgen production and restores HPO axis signalling. Women with significant obesity or insulin-resistant PMOS are most likely to see fertility benefit.

Do I need to stop GLP-1 therapy before trying to conceive?

Yes. Current guidance recommends discontinuing semaglutide at least 2 months before planned conception due to its 7-day half-life and limited human pregnancy safety data. Other GLP-1 agents have different washout timelines. The strategy is to use GLP-1 therapy to restore metabolic and ovulatory function, then plan the pre-conception window with your clinical team to ensure adequate washout before attempting conception.

How long does it take for GLP-1 therapy to restore ovulation in women with PMOS?

Study timelines vary, but improvements in menstrual regularity and ovulatory markers have been observed within 12–26 weeks in multiple trials. One study using low-dose semaglutide (0.5 mg weekly) showed improvements in menstrual cycles alongside weight loss within a treatment period of several months. Individual response depends on baseline weight, degree of insulin resistance, duration of anovulation, and adherence to treatment. A structured monitoring protocol — including cycle tracking and HOMA-IR reassessment — helps identify when the metabolic response is translating into reproductive benefit.

Is GLP-1 therapy better than metformin for fertility in PMOS?

Both improve insulin sensitivity and ovulatory function. GLP-1 RAs produce significantly greater weight loss — often 5–15%+ body weight versus 1–3 kg with metformin — and larger weight loss correlates with better hormonal and reproductive outcomes. GLP-1 agonists also have direct effects on reproductive tissues via GLP-1 receptor expression in the ovary, uterus, and hypothalamus. For women with significant obesity or metformin-resistant insulin resistance, GLP-1 therapy represents a meaningfully stronger metabolic intervention. Combined use with metformin has also been studied and produces additive benefits in some patients.

What metabolic tests should I get before starting GLP-1 therapy for PMOS fertility?

A minimum baseline should include fasting insulin, fasting glucose, HOMA-IR, HbA1c, testosterone (total and free), SHBG, LH, FSH, AMH, and a full lipid and liver panel. Pelvic ultrasound for ovarian morphology is also important. This panel establishes whether insulin resistance is the primary driver of ovulatory failure, quantifies your metabolic burden, rules out contraindications to GLP-1 therapy, and creates a baseline against which treatment response can be tracked at 3-month intervals.

Are GLP-1 effects on fertility permanent?

Current data suggests the benefits are sustained only while treatment continues or while the metabolic gains are maintained. The 2024 durability study following women for two years after semaglutide discontinuation showed partial weight and hormonal regression — though a net benefit from baseline persisted. This underlines that GLP-1 therapy is most effective as part of a long-term metabolic management strategy, not as a short-term intervention. Women who achieve conception and discontinue GLP-1 therapy should have a plan to maintain insulin sensitivity through lifestyle, monitoring, and potentially other pharmacological support as appropriate.